July 23, 2015

WASHINGTON, D.C. - July 23, 2015 - The COPD Patient-Powered Research Network (COPD PPRN) led by the COPD Foundation (COPDF), announces today that it has been approved for a three-year $1.68 million funding award by the Patient-Centered Outcomes Research Institute (PCORI) as part of the second phase of the development of PCORnet, the National Patient-Centered Clinical Research Network. This funding award continues PCORI's support for the COPD PPRN's participation in PCORnet, a large, collaborative research initiative designed to link researchers, patient communities, clinicians, and health systems in productive research partnerships that leverage the power of large volumes of health data maintained by the partner networks. PCORnet will enable the nation to conduct clinical research more quickly and less expensively than is now possible, and will ensure that research focuses on the questions and outcomes that matter most to patients and those who care for them.

PCORI provided $1.0 million to the COPD PPRN during the first phase of PCORnet’s development, which began in the spring of 2014.

As one of 34 health data networks that together make up this national clinical research resource in Phase II, the COPD PPRN is focused on expanding the COPD PPRN and furthering COPD research. The inclusion of patients is essential to success, and patients are involved in all aspects of the COPD PPRN. As the COPD PPRN moves into Phase II of PCORnet, our network is continuing to enroll individuals with COPD and individuals at risk for COPD into a registry with a scalable data hub for the purpose of supporting patient-driven, patient-centered outcomes research. Enrolled patients will represent the spectrum of COPD severity – most with multiple morbidities, across diverse geographic regions, broad age and socio-economic ranges, both genders, and all racial and ethnic groups.

July 09, 2015

WASHINGTON, D.C. - July 9, 2015 - The COPD Foundation is extremely pleased to announce that a new clinical biomarker, plasma fibrinogen, has been approved for use in interventional clinical trials in patients with chronic obstructive pulmonary disease, the nation’s 3rd leading cause of death. This is the first COPD biomarker to receive qualification by the U.S. Food and Drug Administration (FDA) and is the result of six years of work by the COPD Biomarker Qualification Consortium (CBQC).

The CBQC, which includes representatives and resources from university and government research, pharmaceutical and patient communities, was created by the COPD Foundation in 2010, with encouragement from the FDA and the National Heart, Lung and Blood Institute, to develop a “biomarker qualification process” for COPD. Biomarkers are medical processes that researchers use to measure disease severity or to determine if a new drug or treatment is effective. Being able to use a biomarker qualified by the FDA assures drug developers that any potential new drug applications will not be rejected simply because of how the drug’s efficacy was measured or how patients were selected.

“This is a major triumph and, on behalf of the entire COPD community, I extend a heart-felt thank you to the FDA and congratulate the CBQC on its commitment and tireless leadership that allowed us to reach this significant milestone,” said John W. Walsh, co-founder and president of the COPD Foundation. “Individuals working in the pharmaceutical industry, universities and the patient community have spent several million dollars and countless hours assembling and analyzing data that has led to the FDA’s monumental decision to approve this first COPD biomarker. Ultimately this clinical biomarker will enable future drug development to benefit patients.”

May 28, 2015

WASHINGTON, D.C./CHICAGO – May 28, 2015 –The COPD Foundation will host COPD9USA, June 5-6, 2015, at Hyatt Regency O’Hare, Chicago. The event will focus on chronic obstructive pulmonary disease (COPD), the nation's third leading cause of death, providing clinical and scientific knowledge for physicians, nurses, respiratory therapists and anyone involved with the management of individuals with COPD.

"COPD9USA is a unique opportunity to interact face-to-face with thought-leaders in the field and to share practical information for care management, as well as the latest in clinical research,” says John W. Walsh, president and co-founder of the COPD Foundation.

The conference will highlight cutting-edge issues that affect patient care from research, clinical, and care delivery perspectives.

May 07, 2015

WASHINGTON, D.C. – May 7, 2015 – The COPD Foundation released today a video animation, “A Dog’s Life,” to promote awareness and education about chronic obstructive pulmonary disease (COPD), a spectrum of inflammatory lung diseases that include chronic bronchitis and emphysema. Patients with COPD experience chronic respiratory symptoms such as difficulty breathing, wheezing, and coughing.

“A Dog’s Life,” created by Novartis, depicts the daily struggles of life with COPD from the perspective of a patient’s pet. The animated short follows a dog and his owner whose health and untreated symptoms worsen over time. The patient’s quality of life improves once he is introduced to the COPD Foundation’s educational resources and community, COPD360social.org, a unique social networking website for individuals whose lives are affected by COPD.

April 16, 2015

The COPD Foundation would like to congratulate Julie Nimoy, daughter of the late Leonard Nimoy, and HealthPoint Productions for announcing the creation of a documentary, titled COPD: The Logical Way to Improve Lung Function and Breathe Better, which will be released by Health Point Productions in the winter of 2015.

Nimoy, who is best known as the character Mr. Spock from the “Star Trek” television series, died February 27 from complications associated with COPD. 

“In retrospect, I believe my father would have greatly benefited from new information on the latest treatment options available,” said Nimoy’s daughter, Julie Nimoy. “As a special tribute to my father, and to bring more information about COPD to light, I am pleased to announce that my fiancée, David Knight, and I are producing a new documentary film that is going to include the latest advances and treatments available today.” 

April 03, 2015

The American Thoracic Society/European Respiratory Society released a statement on April 2, 2015, which highlights the outstanding knowledge gaps in research questions in chronic obstructive pulmonary disease (COPD). The study aims to describe evidence in terms of diagnosis, assessment and management by identifying gaps in knowledge and recommending ideas for future research. 

March 10, 2015

Since the implementation of the Medicare Durable Medical Equipment Competitive Bidding program which first began implementation 2008 we have become aware of several serious instances where patients have suffered a disruption of service and access to care as it relates to durable medical equipment, particularly many patients who require supplemental being denied their accustomed and prescribed modalities of supplemental oxygen. The COPD Foundation has worked with the Medicare system and patients to ameliorate these problems and has supported policy changes to improve the Competitive Bidding Program.

March 04, 2015

Pfizer has collaborated with the American Pharmacists Association (APhA) and the National Community Pharmacists Association (NCPA) to develop a medication synchronization program for patients who regularly refill more than one medication each month.  The Appointment-based Model (ABM), also called “med sync,” is currently available in more than 10,000 pharmacies and will help patients with chronic conditions to manage prescribed medication properly.

March 03, 2015

The COPD Foundation announced today a groundbreaking initiative to accelerate research and stimulate innovation for chronic obstructive pulmonary disease (COPD), a spectrum of inflammatory lung diseases that include chronic bronchitis and emphysema, with sponsorship from AstraZeneca.  Patients with COPD experience chronic respiratory symptoms such as difficulty breathing and coughing. The COPD360 program will enroll 125,000 patients to databases on an integrated research registry composed of the COPD Patient-Powered Research Network and physician registries. Once fully realized in the next three to five years, COPD360 will combine patient-reported outcomes, clinical data, electronic medical records and observational research into one of the largest COPD research networks ever assembled. Patients entered into the registry have agreed to share their health information and testimonies on how COPD has impacted their lives.

February 27, 2015

The COPD Foundation would like to offer its condolences to the family of Mr. Leonard Nimoy who passed away today at age 83 from chronic obstructive pulmonary disease (COPD).

Mr. Nimoy played the beloved role of Mr. Spock in the original “Star Trek” television series in the mid 1960s.  Mr. Nimoy would later appear in 2009 and 2013 films directed by J.J. Abrams. In addition to his work as a filmmaker, director and writer, Mr. Nimoy used his unique voice for many movie animations and television programs.  

Page 1 of 20First   Previous   [1]  2  3  4  5  6  7  8  9  10  Next   Last   

Join Us on COPD360social

Sign In to Participate
Or register to become a member

Search Press Releases